medigraphic.com
Colegio de Medicina Interna de México.

2025, Number 03

<< Back Next >>

Med Int Mex 2025; 41 (03)

Amiodarone-induced thyroid dysfunction: clinical and therapeutic challenge

Pérez CE, Barrera PLA

Language: Spanish
References: 18
Page: 146-151
PDF size: 353.15 Kb.


ABSTRACT

Objective: To determine the prevalence of amiodarone-induced thyroid dysfunction and its associated risk factors.
Materials and Methods: Retrospective cohort including the outpatient registry from 2018-2022. The groups compared were: a) euthyroid, b) amiodarone-induced hypothyroidism, c) amiodarone-induced hyperthyroidism and d) minor changes.
Results: Out of 153 eligible patients, 18 were analyzed, from which 5 had dysthyroidism: 3 amiodarone-induced hyperthyroidism and 2 amiodarone-induced hypothyroidism. Treatment was longer (82.6 ± 38.1 months) in amiodarone-induced hyperthyroidism than in amiodarone-induced hypothyroidism and euthyroid patients (30.6 ± 29.4 and 28.5 ± 26.1, respectively; p ‹ 0.05). Age over 65 years was negatively associated with thyroid dysfunction (OR 3.8; p ‹ 0.05) and obesity was positively associated (OR: 2.5; p = 0.002).
Conclusions: Amiodarone-induced thyroid dysfunction is frequent; hyperthyroidism was 1.5 times more common than hypothyroidism. Age below 65 years and obesity were identified as risk factors.


REFERENCES

  1. Hamilton D Sr, Nandkeolyar S, Lan H, et al. Amiodarone:A comprehensive guide for clinicians. Am J CardiovascDrugs 2020; 20 (6): 549-558. https://doi.org.10.1007/s40256-020-00401-5

  2. Mujović N, Dobrev D, Marinković M, Russo V, Potpara TS.The role of amiodarone in contemporary management ofcomplex cardiac arrhythmias. Pharmacol Res 2020; 151:104521. https://doi.org.10.1016/j.phrs.2019.104521

  3. Lavon O, Goldman R. Adherence to monitoring guidelinesof amiodarone adverse reactions. Health Serv ResManag Epidemiol 2019; 6: 2333392819844635. https://doi.org.10.1177/2333392819844635

  4. Loke YK, Derry S, Aronson JK. A comparison of three differentsources of data in assessing the frequencies of adverse reactionsto amiodarone. Br J Clin Pharmacol 2004; 57 (5): 616-621. https://doi.org.10.1111/j.0306-5251.2003. 02055.x

  5. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic andcellular mechanisms of action of the most promising classIII agent. Am J Cardiol 1999; 84 (9A): 20R-28R. https://doi.org.10.1016/s0002-9149(99)00698-0

  6. Medić F, Bakula M, Alfirević M, Bakula M, et al. Amiodaroneand thyroid dysfunction. Acta Clin Croat 2022; 61 (2): 327-341. https://doi.org.10.20471/acc.2022.61.02.20

  7. Sohn SY, Inoue K, Rhee CM, Leung AM. Risks of iodine excess.Endocr Rev 2024. https://doi.org.10.1210/endrev/bnae019

  8. Yamato M, Wada K, Fujimoto M, Hosomi K, et al. Associationbetween N-desethylamiodarone/amiodarone ratioand amiodarone-induced thyroid dysfunction. Eur J ClinPharmacol 2017; 73 (3): 289-296. https://doi.org.10.1007/s00228-017-2195-5

  9. Kuczaj A, Warwas S, Danel A, Przybyłowski P, Hrapkowicz T.Thyroid dysfunction in advanced heart failure patients andits correlation with amiodarone therapy: A two-year study.Biomedicines 2024; 12 (3): 567. https://doi.org.10.3390/biomedicines12030567

  10. Maseeh-uz-Zaman, Fatima N, Sajjad Z. Amiodarone therapy:don’t forget thyroid. J Pak Med Assoc 2012; 62 (3): 268-72.

  11. Rahimi-Bashar F, Vahedian-Azimi A, Dalvand S, et al.Prevalence of amiodarone induced hypothyroidism andhyperthyroidism in patients with heart diseases: A systematicreview and meta-analysis. Curr Med Chem 2023;30 (23): 2690-2699. https://doi.org.10.2174/0929867329666220831145651

  12. Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A,et al. 2018 European Thyroid Association (ETA) Guidelinesfor the Management of Amiodarone-Associated ThyroidDysfunction. Eur Thyroid J 2018; 7 (2): 55-66. https://doi.org.10.1159/000486957

  13. Frías López Mdel C, Tárraga López PJ, Rodríguez Montes JA,et al. Hipotiroidismo subclínico y factores de riesgo cardiovascular[Subclinical hypothyroidism and cardiovascularrisk factors]. Nutr Hosp 2011; 26 (6): 1355-1362. https://doi.org.10.1590/S0212-16112011000600024

  14. Ylli D, Wartofsky L, Burman KD. Evaluation and treatmentof amiodarone-induced thyroid disorders. J Clin EndocrinolMetab 2021; 106 (1): 226-236. https://doi.org.10.1210/clinem/dgaa686

  15. Elnaggar MN, Jbeili K, Nik-Hussin N, Kozhippally M,Pappachan JM. Amiodarone-induced thyroid dysfunction:A clinical update [published correction appearsin Exp Clin Endocrinol Diabetes 2018; 126 (6): e1.https://doi.org.10.1055/a-0650-8694]. Exp Clin EndocrinolDiabetes 2018; 126 (6): 333-341. https://doi.org.10.1055/a-0577-7574

  16. Dixon DL, Dunn SP, Kelly MS, McLlarky TR, Brown RE. Effectivenessof pharmacist-led amiodarone monitoring serviceson improving adherence to amiodarone monitoringrecommendations: A systematic review. Pharmacotherapy2016; 36 (2): 230-236. https://doi.org.10.1002/phar.1697

  17. Frenkel A, Smadar Shneyour R, Shiloh A, et al. Adherenceto monitoring of patients treated with amiodarone: a nationwidestudy. Front Med (Lausanne) 2024; 11: 1408799.https://doi.org.10.3389/fmed.2024.1408799

  18. Burgess C, Blaikie A, Ingham T, Robinson G, NarasimhanS. Monitoring the use of amiodarone: compliance withguidelines. Intern Med J 2006; 36 (5): 289-93. https://doi.org.10.1111/j.1445-5994.2006.01068. x




2020     |     www.medigraphic.com